NASDAQ · PGEN
Precigen, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PGEN: Nov 04, 2026
Precigen, Inc. Common Stock is expected to report earnings on 11/04/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $0.09. The reported EPS for the same quarter last year was $-0.11.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.09 | $0.13 | $0.05 | 3 |
| Dec 2026 | $0.12 | $0.20 | $0.06 | 3 |
| Mar 2027 | $0.17 | $0.25 | $0.08 | 2 |
| Jun 2027 | $0.20 | $0.30 | $0.10 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews- Zacks · Oct 29, 9:00 AM EDTC4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseC4 Therapeutics (CCCC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 5, 11:21 AM EDTNovartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen DealNVS gains global rights to Abogen's ABO2203, expanding its RNA therapeutics push with a potential new approach to B-cell-mediated autoimmune diseases.
- Zacks · Oct 5, 10:46 AM EDTUltragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA ValidationRARE's gene therapy for Sanfilippo syndrome wins EMA validation, advancing the treatment toward formal review in Europe.
- Zacks · Oct 5, 10:44 AM EDTPGEN Stock Up More Than 50% in 3 Months: Here's What You Should KnowPrecigen is building momentum with Papzimeos sales growth, a European regulatory review and progress across its AdenoVerse pipeline.
- Zacks · Oct 5, 10:36 AM EDTNovo's Denecimig BLA Review Delayed by FDA Facility Remediation WorkNVO's denecimig FDA review is delayed by manufacturing facility remediation, while no clinical efficacy or safety deficiencies were identified.
- Zacks · Oct 5, 8:29 AM EDTThe Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health CompaniesHealthcare stocks like Abbott Laboratories offer low-beta exposure as rate hike fears and inflation keep markets volatile.
- Zacks · Oct 5, 7:09 AM EDTBeat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in FocusTMO, CRCT and SHOP delivered strong gains as Zacks highlighted standout performers across its research portfolios.
- Zacks · Oct 2, 6:57 AM EDT4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate HikeABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.
- Zacks · Oct 1, 11:16 AM EDTUTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%United Therapeutics secures a key patent ruling against Liquidia, potentially limiting Yutrepia's PH-ILD use and reducing competition for its Tyvaso products.
- RTTNews · Oct 1, 5:04 AM EDTBiotech Stocks At 52-Week Highs – PGEN, EXEL, TWST, HNGE, PBYI(RTTNews) – The following biotech stocks reached a 52-week high on September 30, 2026, driven by key catalysts such as promising results from clinical trials.
- Zacks · Oct 1, 3:35 AM EDTPrecigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?Precigen (PGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- Zacks · Sep 30, 1:34 PM EDTNVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular RiskNovo's real-world study finds that patients who increase their Ozempic to 2 mg have a lower observed MACE risk than those who switch to Mounjaro.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Precigen, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.